Sign-up for Novellia
Create your free online account that allows you to see your medical history all in one place.
Eligibility Criteria
All of the following must apply in order to participate.
You must:
Be 18 years of age or older.
Have ever been diagnosed with breast cancer by a physician.
Have HER2-ultra low* breast cancer.
Be a U.S. resident.
Be able to connect your medical records to your Novellia portal.
Consent to sharing your medical records for the duration of the registry (minimum 9 months)
*HER2-ultralow means that there is a low level of HER2 on cancer cells but not enough HER2 to be considered HER2-positive. If you aren’t sure if you meet the above criteria or have other questions about the registry, please contact us: HER2Horizon@novellia.com or (201) 614-3798
How it Works
We make it easy and rewarding to contribute your insights.
Complete a quick screening
Answer two questions about your breast cancer diagnosis and HER2-status.
Connect your medical records
Connect your medical portals, and Novellia automatically organizes all of your medical history in one place. Once you connect your records and your HER2-ultralow status has been confirmed, you’ll automatically be included in the study. Your data is always kept secure and anonymous.
Participate in future research
You may be eligible to complete surveys and participate in additional research. If you participate in additional research, you’ll earn a gift card for each survey you complete.
Why Join the HER2 Registry?
You may have a newly recognized form of breast cancer, and your experience matters more than ever.
Shape treatment for the future
HER2-ultralow breast cancer is a newly identified subgroup. Your unique treatment journey fills in the gaps that science alone can’t and helps build the evidence base that will shape care for patients like you.
Take control of your health with Novellia
Use Novellia to track and understand your own health data while contributing to research.
Get rewarded for your contributions
Receive a gift card for enrolling + connecting your records.
Each Story Makes an Impact
Your insights will shape the future of breast cancer research.
Meaningful medical advancement relies on real patients. When researchers can connect directly with the people navigating daily life with conditions like HER2-ultralow breast cancer, it helps shape better treatments and care.
.avif)
Shashi Shankar
Novellia CEO & Co-Founder
About Novellia
A powerful patient portal that empowers people living with complex medical conditions.
Easily see your doctor visits, labs, and medications.
New medical records are automatically added from connected portals.
Add your own notes to make sure no key details get lost.
Access appointment guides to help you prepare for doctor visits.
Your data is always kept secure and private.
Trusted by patient advocacy groups
Frequently Asked Questions
Participation is easy and anonymous—learn more below.
Do I need to go somewhere in person to participate in the study?
No, you can connect to the Novellia portal from the comfort of home.
How much time should I plan to spend on participating in the study?
For now, you’ll just need to spend < 10 minutes onboarding and connecting your records to Novellia. In the future, you may be eligible to spend less than 10 minutes a month to complete surveys to contribute to additional research. You’ll be compensated with a gift card each time you complete a survey.
How is my data protected?
Your privacy is our top priority. Novella keeps your personal health data secure in our encrypted, HIPPA-compliant app and your survey responses are always anonymous.
How is this study helping people living with HER2-ultra low breast cancer?
By sharing your health information, you can benefit individuals affected by HER2-ultralow breast cancer by helping researchers to gain a better understanding of this condition, and improve patient care. Topics of study include:
- Enhancing the understanding of patients with HER2-ultra low breast cancer
- Identifying health outcomes associated with different treatments for HER2-ultralow breast cancer
- Supporting the development of new medicines for HER2-ultralow breast cancer